Vyome Holdings, Inc. (NASDAQ:HIND) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Vyome Holdings, Inc. (NASDAQ:HIND) have been assigned an average recommendation of “Hold” from the five brokerages that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have given a buy recommendation to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $15.00.

Several analysts have recently commented on HIND shares. Zacks Research upgraded shares of Vyome to a “hold” rating in a report on Wednesday, May 6th. Litchfield Hills Research started coverage on shares of Vyome in a report on Monday, May 4th. They issued a “buy” rating for the company. Finally, Weiss Ratings upgraded shares of Vyome from a “sell (e)” rating to a “sell (e+)” rating in a report on Friday, May 1st.

Institutional Trading of Vyome

An institutional investor recently bought a new position in Vyome stock. Millennium Management LLC acquired a new position in shares of Vyome Holdings, Inc. (NASDAQ:HIND) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 45,144 shares of the company’s stock, valued at approximately $155,000. Millennium Management LLC owned about 0.80% of Vyome as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 22.06% of the company’s stock.

Vyome Price Performance

Shares of HIND stock opened at $2.32 on Tuesday. The firm has a 50-day moving average of $2.17 and a 200-day moving average of $3.02. The company has a market cap of $16.29 million, a P/E ratio of -0.19 and a beta of 1.48. Vyome has a one year low of $1.75 and a one year high of $33.16.

Vyome (NASDAQ:HIND) last announced its earnings results on Tuesday, May 12th. The company reported ($0.15) EPS for the quarter. The firm had revenue of $0.03 million during the quarter. Vyome had a negative net margin of 270.58% and a negative return on equity of 203.92%. As a group, research analysts expect that Vyome will post -0.6 earnings per share for the current fiscal year.

Vyome Company Profile

ReShape Lifesciences Inc, a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company’s product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract.